Gretchen L. Gierach, Ph.D., M.P.H.
Metabolic Epidemiology Branch
9609 Medical Center Drive
Rockville, MD 20850
Dr. Gretchen Gierach is interested in the study of the etiology of hormonally-related female cancers, particularly in the molecular mechanisms underlying breast carcinogenesis. Her interdisciplinary research program has a special emphasis on the molecular epidemiology of mammographic density, one of the strongest risk factors for breast cancer.
Molecular Epidemiologic Studies of Mammographic Density and Breast Cancer Risk
The tissue composition of the breast is reflected mammographically by the pattern of distribution of fibroglandular and fatty tissue. A higher component of fat results in lower mammographic density. Conversely, a higher proportion of fibroglandular tissue results in greater density. Studies have consistently demonstrated that high mammographic density is a strong breast cancer risk factor. Therefore, understanding factors that affect mammographic density and their underlying mechanisms are important--yet understudied--research questions.
The BREAST Stamp Project aims to characterize the radiologic, histologic, and molecular features of dense breast tissue and to understand how the microenvironment of dense breasts promotes neoplastic transformation of the breast epithelium. Data relating mammographic density to molecular markers of breast cancer are limited. To correlate mammographic density to molecular profiles of breast tissues, we are currently leveraging the resources of HREB’s Breast Cancer Case-Control Study in Poland, a population-based case-control study conducted in Lódz and Warsaw from 2000-2003. We have collected mammograms for density assessment from a subset of the study’s cancer cases, along with breast tissues that were snap frozen and analyzed using mRNA profiling.
Epidemiologic risk factors strongly associated with mammographic density, such as age and body mass index, explain only about 20% to 30% of the variation in density. The remaining variation in mammographic density is thought to be, in part, genetically determined. We are therefore conducting several investigations designed to address the role of genes in mammographic density. In collaboration with DCEG’s Clinical Genetics Branch, we are examining whether mammographic density and computer-extracted mammographic texture pattern features differ by BRCA1/2 mutation status.
In addition to addressing how molecular epidemiologic factors may influence mammographic density and its associated breast cancer risk, I am also addressing other ways in which density may relate to breast carcinogenesis. In light of emerging evidence indicating that reductions in mammographic density may predict response to tamoxifen treatment, my colleagues and I initiated a study within Kaiser Permanente Northwest to determine whether breast cancer patients who experience large reductions in density following tamoxifen treatment have an improved prognosis. We have also launched the Ultrasound Study of Tamoxifen, in which we are using novel ultrasound tomography methods to assess changes in volumetric breast density within the first year of tamoxifen therapy. These studies may provide support for future investigations evaluating change in mammographic density as a “biosensor” of factors that increase or decrease breast cancer risk.
Dr. Gierach earned both her M.P.H. (2004) and Ph.D. (2006) degrees in epidemiology from the University of Pittsburgh with a focus in cancer epidemiology and women’s health. She joined the Hormonal and Reproductive Epidemiology Branch (HREB) as a NCI Cancer Prevention Fellow in 2006 became a tenure-track investigator in 2010, and was awarded NIH scientific tenure in 2017. Dr. Gierach has been awarded the Division of Cancer Epidemiology and Genetics (DCEG) Molecular Epidemiology Research Funding Award, the NCI Merit Award in Cancer Prevention Research Training, and an Award to Advance Research on Cancers in Women from the NCI Office of Science Planning and Assessment and the NIH Office of Research on Women’s Health. Dr. Gierach serves as DCEG’s representative to the NIH Intramural Program on Research on Women's Health Steering Committee and the NCI Women’s Health Activities Committee, and is an active member of the DENSNP and Marker Of Density (MODE) Consortia on the genetics of mammographic density.
Sampson JN, Falk RT, Schairer C, Moore SC, Fuhrman BJ, Dallal CM, Bauer DC, Dorgan JF, Shu XO, Zheng W, Brinton LA, Gail MH, Ziegler RG, Xu X, Hoover RN, Gierach GL. Association of Estrogen Metabolism with Breast Cancer Risk in Different Cohorts of Postmenopausal Women. Cancer Res. 2017;77(4):918-925.
Gierach GL, Curtis RE, Pfeiffer RM, Mullooly M, Ntowe EA, Hoover RN, Nyante SJ, Feigelson HS, Glass AG, Berrington de Gonzalez A. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncol. 2017;3(2):186-193.
Sun X, Gierach GL, Sandhu R, Williams T, Midkiff BR, Lissowska J, Wesolowska E, Boyd NF, Johnson NB, Figueroa JD, Sherman ME, Troester MA. Relationship of mammographic density and gene expression: analysis of normal breast tissue surrounding breast cancer. Clin Cancer Res. 2013;19(18):4972-4982.
Gierach GL, Ichikawa L, Kerlikowske K, Brinton LA, Farhat GN, Vacek PM, Weaver DL, Schairer C, Taplin SH, Sherman ME. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst. 2012;104(16):1218-27.
Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, Hoover RN, Glass A, Gierach GL. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. J Natl Cancer Inst. 2015;107(3).
Related Scientific Focus Areas
Genetics and Genomics
This page was last updated on May 1st, 2017